An Old Pharmacological Agent, the Newest Antidepressant: Gepirone

Year 2024, , 68 - 70, 30.06.2024

Doğancan Sönmez

https://doi.org/10.59518/farabimedj.1436648

Abstract

Extended-release Gepirone HCL (gepiron ER; EXXUATM), which can be administered once daily, is formulated as a selective serotonin (5HT)1A receptor agonist. This medication is designed to be effective in adult patients for the treatment of psychiatric disorders, including major depressive disorder (MDD). In September 2023, Gepiron ER received official approval in the United States for the treatment of adults diagnosed with MDD. This article presents literature information about Gepiron, the newest antidepressant to receive FDA approval for the treatment of adults with MDD.

Keywords

Antidepressant, Gepirone, Depression, Treatment

Eski Bir Farmakolojik Ajan, En Yeni Antidepresan: Gepiron

Abstract

Günde bir kez uygulanabilen uzatılmış salınımlı Gepirone HCL (gepiron ER; EXXUATM), selektif serotonin (5HT)1A reseptör agonisti olarak formüle edilmiştir. Bu ilaç, psikiyatrik bozuklukların tedavisi için özellikle majör depresif bozukluk (MDB) dahil olmak üzere, yetişkin hastalarda etkili olabilecek şekilde tasarlanmıştır. Eylül 2023'te, Gepiron ER, MDB tanısı almış yetişkinlerin tedavisi için Amerika Birleşik Devletleri'nde resmi onay almıştır. Bu makale, MDB'li yetişkinlerin tedavisi için FDA onayı alan en yeni antidepresan olan Gepiron hakkındaki literatür bilgileri sunulmaktadır.

Keywords

Antidepresan, Gepiron, Depresyon, Tedavi

References

• Keam SJ. Gepirone extended-release: First Approval. Drugs. 2023;83(18):1723-1728. doi:10.1007/s40265-023-01975-5
• Aschenbrenner DS. New drug class for major depressive disorder. Am J Nurs. 2024;124(2):18-19. doi:10.1097/01.NAJ.0001006684.66510.11
• Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol. 1990;10(3 Suppl):6S-12S. doi:10.1097/00004714-199006001-00003
• Moodliar S, Naguy A, Elsori DH. Add-on mirtazapine to clozapine-responsive early-onset schizophrenia. Psychiatry Res. 2020;284:112701. doi:10.1016/j.psychres.2019.112701
• Naguy A, Elsori D, Alamiri B. Methylphenidate-induced nocturnal bruxism alleviated by adjunctive clonidine. J Child Adolesc Psychopharmacol. 2019;29(1):75-76. doi:10.1089/cap.2018.0114
• Fabre LF, Brown CS, Smith LC, Derogatis LR. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med. 2011;8(5):1411-1419. doi:10.1111/j.1743-6109.2011.02216.x
• Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(3):243-249.
• Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008;69(4):571-577. doi:10.4088/jcp.v69n0408
• Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol. 2005;25(1):79-84. doi:10.1097/01.jcp.0000150221.53877.d9
• Naguy A. Gepirone-the latest antidepressant on market state of the art or run of the mill?. Asian J Psychiatr. 2024;94:103937. doi:10.1016/j.ajp.2024.103937